HIV/AIDS Clinical Trials

Find HIV/AIDS Clinical Trials Near You

Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors (TATI HOPE Act)

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), published Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. All such transplants must occur under an institutional review board (IRB) approved research protocol that is compliant with federal regulations governing human subjects research. This is an investigator-initiated, observational prospective study of solid organ transplantation utilizing HIV-positive donors in HIV positive recipients. Stable HIV-infected adults in need of a solid organ transplant (kidney) who meet standard and study specified HIV criteria for organ transplantation will be offered enrollment in the study. Deceased donors (kidney) and living donors (kidney) will be utilized in this protocol. The goal of this research is to increase knowledge about the safety, efficacy, and effectiveness of solid organ transplantation (SOT) utilizing HIV-positive donors in HIV-positive recipients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participant meets standard listing criteria for transplant.

• Greater than or equal to 18 years of age.

• Participant has documented HIV infection using an FDA-licensed, approved, or cleared test device(s).

• CD4+ T-cell count ≥200/μL within 16 weeks prior to transplant; any patient with history of Opportunistic Infections must have a CD4 positive T-cell count ≥200/uL.

• HIV RNA less than 50 copies/mL and on a stable antiretroviral regimen.

• No evidence of active opportunistic complications of HIV infection.

• On a stable antiretroviral regimen. Participants unable to tolerate ART due to organ failure may still be considered eligible if the study team is confident there will be a safe, tolerable, and effective antiretroviral regimen once organ function is restored after transplantation.

• No history of primary CNS lymphoma or progressive PML

Locations
United States
Louisiana
East Jefferson General Hospital
RECRUITING
Metairie
Contact Information
Primary
Alfred Luk, MD,
aluk@tulane.edu
(504) 988-7316
Backup
Delainna Bartholomew, BS
dbartho@tulane.edu
504-988-6902
Time Frame
Start Date: 2021-11-15
Estimated Completion Date: 2026-11
Participants
Target number of participants: 30
Treatments
Kidney transplant recipients
Up to 25 HIV-positive participants requiring kidney organ transplantation
Kidney living donors
Up to 5 HIV-positive living donors will be enrolled.
Related Therapeutic Areas
Sponsors
Leads: Tulane University

This content was sourced from clinicaltrials.gov